A traditional Chinese medicine for treating rheumatoid arthritis containing paederosida saponins and a preparation method thereof

Abstract

The application relates to the field of traditional Chinese medicines, and discloses a traditional Chinese medicine containing Radix Sargentodoxae for treating rheumatic arthritis and a preparation method thereof. The traditional Chinese medicine contains the following components in parts of mass: 30-50 parts of Radix Sargentodoxae, 10-20 parts of Radix Cyathulae, 10-20 parts of Rhizoma Chuanxiong, 10-20 parts of Radix Paeoniae Alba, 5-10 parts of Fructus Lycii, and 5-10 parts of Radix Rehmanniae. The preparation method comprises the following steps: crushing the Radix Sargentodoxae, Radix Cyathulae, Rhizoma Chuanxiong, Radix Paeoniae Alba, Fructus Lycii and Radix Rehmanniae; extracting medicinal components of the above-mentioned medicinal materials; mixing the extract with phospholipids or polymers to form liposomes; the liposomes are pH-responsive nanoliposomes or temperature-responsive nanoliposomes; preparing the nanoliposomes through a film hydration method or a layer-by-layer self-assembly method; and obtaining the traditional Chinese medicine through filtration and drying. The pH-responsive and temperature-responsive nanoliposomes can precisely release the medicine to an inflammation area, ensure that the medicine is released only in a place where treatment is needed, and improve the treatment effect.

Description

Technical Field

[0001] The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine for treating rheumatoid arthritis containing angelica vine and a preparation method thereof. Background Art

[0002] In modern medicine, rheumatoid arthritis (RA) is a common chronic immune disease characterized by joint inflammation, swelling, and pain, severely impacting patients' quality of life. Although a variety of drugs are currently available for the treatment of RA, existing treatments still have significant shortcomings, particularly in terms of drug delivery systems. Traditional drug delivery methods, such as oral, topical, or injectable, often suffer from poor drug targeting, unstable drug release rates, and inability to precisely reach the site of inflammation. The absorption, distribution, and metabolism of most drugs in the body vary significantly from individual to individual, and many are easily metabolized or degraded during passage through the liver or intestinal barrier, resulting in reduced efficacy or increased side effects. Furthermore, while existing nano-drug delivery systems have achieved some progress, they still face challenges such as difficulty in precisely controlling drug release rates and ensuring sustained and stable drug release. In particular, the drug release process of some traditional nano-liposomes depends primarily on the physical properties of the carrier, such as particle size and surface charge. These factors are often difficult to precisely regulate in the complex in vivo environment, resulting in unstable drug release and the inability to achieve long-term, sustained therapeutic effects. When treating rheumatoid arthritis, drugs must be released continuously and stably, precisely targeting the affected area to minimize side effects and improve efficacy. Traditional drug delivery systems often fail to address this issue. The drugs are distributed throughout the body and fail to effectively target the site of inflammation, thus failing to fully exert their efficacy and resulting in unsatisfactory treatment results. Summary of the Invention

[0003] In response to the shortcomings of the existing technology, the present invention provides a traditional Chinese medicine for treating rheumatoid arthritis containing Angelica Root and a preparation method thereof, which solves the problems in the existing technology such as poor drug targeting, unstable drug release rate, and failure of the drug to accurately reach the site of inflammation.

[0004] To achieve the above objectives, the present invention is implemented through the following technical solutions: A Chinese medicine for treating rheumatoid arthritis containing Angelica sinensis vine, comprising the following components in parts by mass:

[0005] 30-50 parts of Angelica Root;

[0006] 10-20 servings of Achyranthes bidentata;

[0007] 10-20 parts of Chuanxiong;

[0008] 10-20 parts of white peony root;

[0009] 5-10 servings of wolfberries;

[0010] 5-10 parts of raw Rehmannia root.

[0011] A method for preparing a Chinese medicine for treating rheumatoid arthritis containing angelica vine, comprising the following steps:

[0012] Crush angelica vine, Achyranthes bidentata, Chuanxiong rhizome, white peony root, wolfberry fruit and raw rehmannia root;

[0013] extracting medicinal components from the above medicinal materials;

[0014] The extract is mixed with phospholipids or polymers to form liposomes, wherein the liposomes are pH-responsive nanoliposomes or temperature-responsive nanoliposomes;

[0015] Nanoliposomes were prepared by thin film hydration or layer-by-layer self-assembly methods;

[0016] The Chinese medicine for treating rheumatoid arthritis containing angelica vine is obtained by filtering and drying.

[0017] Preferably, the pH-responsive nanoliposomes are prepared by a thin film hydration method, and the surface of the liposomes is modified with polyvinyl alcohol or polyacrylate.

[0018] Preferably, the temperature-responsive nanoliposomes are prepared by a layer-by-layer self-assembly method, and the outer layer of the liposomes is a temperature-responsive polymer PNIPAM.

[0019] Preferably, the drug loading of the nanoliposomes is 1-5% (w / v).

[0020] Preferably, the medicinal material is ground into a particle size of 30-50 mesh.

[0021] Preferably, the particle size of the nanoliposome is controlled at 100-200 nm.

[0022] Preferably, the extraction time of the extract is 30-60 minutes, and the extraction temperature is 40-60°C.

[0023] A traditional Chinese medicine preparation for treating rheumatoid arthritis is prepared by preparing the traditional Chinese medicine for treating rheumatoid arthritis containing angelica vine as claimed in claim 1 into pills or tablets.

[0024] Preferably, the traditional Chinese medicine preparation is used for preparing a medicine for treating rheumatoid arthritis.

[0025] The present invention provides a Chinese medicine for treating rheumatoid arthritis containing angelica vine and a preparation method thereof. It has the following beneficial effects:

[0026] 1. The present invention uses pH-responsive and temperature-responsive nanoliposomes to precisely release drugs to the inflamed area. Compared with the prior art where traditional drugs directly enter the body, resulting in unstable efficacy or difficulty in accurately reaching the lesion, the present invention ensures that drugs are released only where treatment is needed, thereby improving the therapeutic effect.

[0027] 2. By optimizing the liposome preparation method, the present invention controls the amount and rate of drug release. Compared to existing technologies, which tend to release drugs prematurely or lose their effectiveness, the present invention enables sustained drug release, ensuring that the drug maintains its therapeutic effect over a long period of time, reducing the need for patients to take medication frequently.

[0028] 3. This invention uses responsive materials to ensure that the drug is released and maintains its effect in the affected area. Compared with existing technologies, the drug can act more precisely on the affected area of ​​rheumatoid arthritis during treatment, reducing the impact on other healthy areas, making treatment more efficient and direct. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 It is a schematic diagram of the preparation process of the present invention. DETAILED DESCRIPTION

[0030] The following will clearly and completely describe the technical solution of the present invention in conjunction with the accompanying drawings. Obviously, the embodiments described are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of the present invention.

[0031] Example 1: Preparation of pH-responsive nanoliposomes

[0032] Please see the attached Figure 1 , steps and process parameters:

[0033] Take Angelica sinensis vine (35 parts), Achyranthes bidentata (15 parts), Chuanxiong (12 parts), White Peony Root (12 parts), Lycium barbarum (7 parts) and Rehmannia root (6 parts), and crush them into 30 mesh size to ensure that the active ingredients of the medicinal materials can be fully released.

[0034] Using ultrasonic extraction, the herbal powder was mixed with a 60% ethanol solution at a ratio of 1:5 for 40 minutes at a temperature of 50°C. The extract was then filtered and concentrated.

[0035] Phospholipids (15 g) and polyacrylate (5 g) were dissolved in dichloromethane and the solvent was removed by rotary evaporation to form a lipid film. The extract (pH 4.8 hydration solution) was then added for hydration at 50°C for 60 minutes. This step ensured that the active pharmaceutical ingredient was encapsulated within the liposomes.

[0036] The liposomes were dispersed by ultrasonic treatment to stabilize their particle size between 100-200 nanometers. The drug loading was 2.5% (w / v), ensuring that the liposomes could stably carry the drug and release it locally.

[0037] The liposomes without drug were removed by 0.22 μm filtration to ensure the purity of the preparation. The final drug preparation was stored at -20°C to ensure its stability.

[0038] Example 2:

[0039] Steps and process parameters:

[0040] Take angelica vine (40 parts), Achyranthes bidentata (18 parts), Chuanxiong (15 parts), white peony root (12 parts), wolfberry fruit (6 parts) and raw rehmannia root (9 parts), and grind them into 40 mesh.

[0041] Using the maceration extraction method, the medicinal materials were soaked in 70% ethanol at a ratio of 1:6 for 50 minutes, and then filtered and concentrated to obtain the medicinal solution.

[0042] Phospholipids (10 g) and PNIPAM (2 g) were dissolved in chloroform (20 ml). The solvent was removed by rotary evaporation to form a lipid film. The liposomes were then hydrated with the extract (pH 5.0) at 60°C for 60 minutes to ensure uniform encapsulation of the drug.

[0043] Using a layer-by-layer self-assembly method, different polymer layers were gradually added to ultimately produce 150nm nanoliposomes with a controlled drug loading of 3% (w / v).

[0044] The drug release rate was tested at 32°C and 37°C. At 37°C, PNIPAM undergoes a phase transition, accelerating drug release. The test results show that increasing the temperature significantly increases the drug release rate.

[0045] After filtering through a 0.22 μm filter membrane, the liposomes were stored at low temperature to ensure their stability.

[0046] Example 3:

[0047] Steps and process parameters:

[0048] Crush Angelica sinensis vine (50 parts), Achyranthes bidentata (10 parts), Ligusticum chuanxiong (10 parts), White Peony Root (10 parts), Lycium barbarum (5 parts) and Rehmannia root (5 parts) into 40 mesh size.

[0049] Using ultrasonic extraction method, the medicinal materials were mixed with 60% ethanol solution in a ratio of 1:5, the extraction time was 45 minutes, the extraction temperature was 50℃, and then the extract was filtered and concentrated.

[0050] Using the thin film hydration method, phospholipids (10 g) and polyvinyl alcohol (5 g) were dissolved in chloroform and rotary evaporated to form a thin film. The extract (pH 5.5 hydration solution) was added for hydration at 50°C for 45 minutes.

[0051] Ultrasonication and high-pressure homogenization were used to control the particle size within 120 nm. The drug loading was 3.0% (w / v) to ensure uniform drug distribution.

[0052] The final formulation was obtained by filtering through a 0.22 μm filter membrane to remove liposomes without drug encapsulation, and stored at low temperature.

[0053] Example 4:

[0054] Steps and process parameters:

[0055] Crush Angelica sinensis (40 parts), Achyranthes bidentata (15 parts), Ligusticum chuanxiong (12 parts), White Peony Root (10 parts), Lycium barbarum (8 parts) and Rehmannia root (5 parts) into 50 mesh.

[0056] The traditional decoction method was adopted, and the medicinal materials and water were decocted at a ratio of 1:6 for 60 minutes. The decoction was taken, filtered and concentrated to obtain a concentrated solution.

[0057] The concentrate is dried by spray drying to form granular drugs, and finally formed into tablets by tablet compression.

[0058] Example 5: Comparison of conventional and responsive liposome preparations

[0059] Steps and process parameters:

[0060] Crush Angelica sinensis (30 parts), Achyranthes bidentata (10 parts), Ligusticum chuanxiong (15 parts), White Peony Root (10 parts), Lycium barbarum (8 parts) and Rehmannia root (7 parts) into 50 mesh.

[0061] The ultrasonic extraction method was used, the extraction solution was 50% ethanol, the extraction ratio was 1:6, the extraction time was 40 minutes, and the temperature was 45°C to obtain the medicinal solution.

[0062] Liposomes were prepared using conventional phospholipids (10 g) and polyvinyl alcohol (5 g) by the thin film hydration method without the use of responsive materials.

[0063] Comparative experiment 1: Traditional preparation method vs pH-responsive nanoliposomes

[0064] Comparison conditions:

[0065] Traditional preparation method:

[0066] After the medicinal materials are crushed, the medicinal liquid is extracted using the traditional decoction method, the medicinal liquid is dried into granules by spray drying, and the tablet is pressed into a tablet to make the medicine.

[0067] The drug was used via conventional tablet preparation methods with a drug loading of 5% (w / v), but no nanoliposome technology was used and no responsive material modification was performed.

[0068] pH-responsive nanoliposomes:

[0069] Liposomes are prepared using a thin film hydration method and pH-responsive polymers (e.g., polyacrylates). The drug loading is controlled at 2.5% (w / v) and the liposome particle size is controlled within the 100-200 nm range, ensuring drug release in a localized acidic environment for enhanced targeting and therapeutic efficacy.

[0070] the difference:

[0071] Traditional methods cannot achieve precise drug release, resulting in low drug bioavailability and unstable therapeutic effects. In contrast, pH-responsive liposomes can ensure drug release in a local acidic environment, improving drug targeting and efficacy.

[0072] Comparative Experiment 2: No Responsive Polymer vs. Temperature-Responsive Nanoliposomes

[0073] Comparison conditions:

[0074] Without using responsive polymer:

[0075] The drug is prepared into liposomes using conventional phospholipids and polyvinyl alcohol. The particle size is controlled at 300 nm, the drug loading is 3% (w / v), and there is no adjustment for temperature changes. The drug release process is relatively stable, but cannot be precisely adjusted.

[0076] Temperature-responsive nanoliposomes:

[0077] Liposomes were prepared by layer-by-layer self-assembly using temperature-responsive polymers such as PNIPAM. The particle size was controlled to 150 nm, and the drug loading was 3% (w / v). When the local temperature rises, the liposomes undergo a phase transition, promoting drug release.

[0078] the difference:

[0079] Liposomes without responsive polymers cannot regulate drug release with temperature changes, resulting in a relatively stable drug release and lacking the advantage of precise localized release. Temperature-responsive nanoliposomes can better control the release rate of drugs in the inflamed area, increasing the therapeutic effect.

[0080] Comparative Experiment 3: Traditional Drug Loading vs. Drug Loading of the Present Invention

[0081] Comparison conditions:

[0082] Traditional drug loading:

[0083] The drug loading amount is usually 5% (w / v), and the drug is loaded through traditional tablet or granule preparation methods. However, common disadvantages of this method are uneven distribution of the drug in the body and too rapid drug release, which affects the efficacy.

[0084] Drug loading of the present invention:

[0085] The drug loading is controlled in the range of 2.5%-3% (w / v), and precise drug delivery is carried out through pH-responsive or temperature-responsive nanoliposomes to ensure that the drug can be effectively released in a specific area within the required time.

[0086] the difference:

[0087] Traditional drug loading is high, but the drug is released too quickly, resulting in discontinuous therapeutic effects and even drug waste. The present invention controls the drug loading to ensure sustained release of the drug at an appropriate concentration, thereby improving the therapeutic effect and bioavailability.

[0088] Comparative Experiment 4: Traditional Particle Size Control vs. Nanoliposome Particle Size Control

[0089] Comparison conditions:

[0090] Traditional particle size control:

[0091] Drug particle size is usually large, controlled at around 300 nm. Liposomes with larger particle size may cause immune responses in the body or be quickly cleared by organs such as the liver and spleen, reducing the bioavailability and targeting of the drug.

[0092] Nanoliposome particle size control:

[0093] The present invention adopts ultrasonic treatment and high-pressure homogenization to accurately control the particle size of the liposome within the range of 100-200 nm. Such a particle size is conducive to improving the permeability and uptake efficiency of the drug.

[0094] the difference:

[0095] Traditionally, the controlled particle size of the nanoliposomes is too large, which can lead to premature drug excretion or uneven distribution in the body. However, the controlled particle size of the nanoliposomes in this invention allows them to effectively penetrate the site of inflammation, increasing the drug's efficacy and reducing the impact on other healthy tissues.

[0096] Comparative Experiment 5: Traditional Drug Release Rate vs. Responsive Drug Release of the Present Invention

[0097] Comparison conditions:

[0098] Traditional drug release rate:

[0099] When drugs are delivered through conventional pharmaceutical formulations, the release rate is usually linear, with the drug being released rapidly for a short period of time and then losing efficacy, resulting in a short-lasting therapeutic effect.

[0100] Responsive drug release of the present invention:

[0101] The pH-responsive or temperature-responsive liposomes of the present invention can adjust the drug release rate according to the acidity or temperature changes in the lesion area. In the inflamed area, drug release is accelerated, providing a sustained therapeutic effect.

[0102] the difference:

[0103] Traditional drug release rates cannot be adjusted according to changes in the lesion environment, resulting in limited therapeutic effectiveness. In contrast, the present invention can precisely regulate drug release, ensuring that the drug efficacy remains stable during treatment.

[0104] Experimental design:

[0105] This experiment aims to verify the effectiveness of the present invention and further demonstrate its innovativeness and practical application by comparing different drug delivery systems and methods in the examples and comparative experiments. All experiments will follow a strict single-factor comparative design to ensure the reliability and comparability of the experimental results.

[0106] Experiment 1: Comparison of drug release rates

[0107] Purpose:

[0108] The difference in drug release rate between pH-responsive nanoliposomes and conventional nanoliposomes was verified, further demonstrating the precise release effect of the drug in the present invention under specific conditions.

[0109] Experimental setup:

[0110] Experimental group:

[0111] The pH-responsive nanoliposomes prepared in Example 1 were used, with a drug loading of 2.5% (w / v), a particle size of 150 nm, and a hydration solution pH of 4.8.

[0112] Comparison group:

[0113] Using the traditional drug delivery method in comparative experiment 1, conventional phospholipid liposomes were prepared with a drug loading of 5% (w / v), a particle size of 300 nm, and a hydration solution pH of 7.4.

[0114] Experimental methods:

[0115] The above two groups of samples were added into simulated solutions with different pH values ​​(pH 4.8 and pH 7.4), and the temperature was set at 37°C for the experiment to simulate the in vivo environment.

[0116] At predetermined time points (e.g., 1 h, 3 h, 6 h, and 12 h), samples were taken and the drug concentration was determined by UV-visible spectrophotometry.

[0117] Draw the drug release curve and compare the drug release amounts at different time points.

[0118] Comparison table:

[0119] Time (hours) Example 1 (pH-responsive nanoliposomes) Drug release (%) Comparative experiment 1 (traditional liposomes) drug release (%) 1 25% 5% 3 45% 20% 6 70% 40% 12 85% 60%

[0120] Expected results:

[0121] The pH-responsive nanoliposomes of the present invention undergo a protonation reaction in an acidic environment, resulting in rapid drug release. Compared with traditional liposomes, the drug release is faster and more concentrated in the initial stage.

[0122] Traditional liposomes release drugs slowly and evenly in a neutral environment, and their effects are not as precise as those of the present invention.

[0123] Experiment 2: Comparison of temperature-responsive drug release

[0124] Purpose:

[0125] Verify the drug release effect of temperature-responsive nanoliposomes and liposomes without responsive materials in comparative experiment 2 when the temperature rises.

[0126] Experimental setup:

[0127] Experimental group:

[0128] The temperature-responsive nanoliposomes described in Example 2 were used, with a drug loading of 3% (w / v), a particle size of 150 nm, and PNIPAM as the responsive polymer.

[0129] Comparison group:

[0130] Ordinary polymer liposomes in comparative experiment 2 were used with a drug loading of 3% (w / v) and a particle size of 300 nm, and no temperature-responsive polymer was used.

[0131] Experimental methods:

[0132] The above two groups of samples were placed in an environment of 32°C and 37°C respectively to simulate the temperature changes of rheumatoid arthritis lesions.

[0133] Samples were taken at regular intervals, and the drug concentration was determined using a UV-visible spectrophotometer, and the drug release curve was plotted.

[0134] Compare the drug release rates under temperature changes.

[0135] Comparison table:

[0136] Time (hours) Example 2 (Temperature-responsive nanoliposomes, 37°C) Drug release (%) Comparative experiment 2 (conventional liposomes, 37°C) drug release (%) 1 30% 10% 3 55% 25% 6 80% 50% 12 95% 65%

[0137] Expected results:

[0138] The temperature-responsive nanoliposomes in Example 2 can quickly release drugs at 37° C., reflecting its temperature-responsive characteristics.

[0139] The release rates of the ordinary liposomes in the control group were almost the same at 32° C. and 37° C., lacking temperature responsiveness. The release rate was relatively stable, and the therapeutic effect of the drug was not as obvious as that in Example 2.

[0140] Experiment 3: Comparison of particle size and drug permeability

[0141] Purpose:

[0142] The differences in drug permeability and targeting between the nanoliposomes with controlled particle size in the present invention and traditional liposomes were verified, proving that the present invention can better achieve targeted release of drugs in rheumatoid arthritis.

[0143] Experimental setup:

[0144] Experimental group:

[0145] The nanoliposomes in Example 3 were used, with a particle size of 120 nm and a drug loading of 3% (w / v). The particle size was controlled by ultrasonic treatment and high-pressure homogenization.

[0146] Comparison group:

[0147] The conventional liposomes used in comparative experiment 3 had a particle size of 300 nm and a drug loading of 5% (w / v), and no particle size optimization was performed.

[0148] Experimental methods:

[0149] The above two groups of samples were injected into rheumatoid arthritis mouse models to observe the drug's ability to penetrate into joint tissue.

[0150] Using tissue sectioning technology, joint tissue is cut and the distribution of the drug in the tissue is observed under a microscope.

[0151] The cumulative concentration of drugs in joint tissues was calculated and statistical analysis was performed.

[0152] Comparison table:

[0153] Group Particle size (nm) Drug permeability (cumulative concentration in joint tissue, μg / g) Example 3 (Nanoliposomes) 120 15.6 Comparative Experiment 3 (Traditional Liposomes) 300 8.2

[0154] Expected results:

[0155] The particle size of the nanoliposomes in Example 3 is controlled at 120 nm, which can more effectively penetrate into the joint area, and the cumulative concentration of the drug in the joint area is higher.

[0156] Traditional liposomes have large particle sizes and poor drug permeability, and thus fail to effectively accumulate in the joint area, resulting in a significantly lower therapeutic effect than the present invention.

[0157] Experiment 4: Comparison of drug loading

[0158] Purpose:

[0159] The differences in drug release and therapeutic effects between the optimized drug loading amount in the present invention and the traditional drug loading amount were verified.

[0160] Experimental setup:

[0161] Experimental group:

[0162] The nanoliposomes in Example 3 were used, with a drug loading of 3% (w / v), a particle size controlled at 120 nm, and an effective drug release of 2.5% (w / v).

[0163] Comparison group:

[0164] Using traditional liposomes in comparative experiment 3, the drug loading was 5% (w / v), the particle size was 300 nm, and the drug was released too quickly.

[0165] Experimental methods:

[0166] The drug preparation is applied to the rheumatoid arthritis animal model by oral or topical administration.

[0167] Samples were taken regularly to measure the drug concentrations in serum and joint fluid, and a curve showing the changes in drug concentration over time was drawn.

[0168] Observe the reduction of inflammation in the joints and the therapeutic effect, and record the duration of the drug's efficacy.

[0169] Comparison table:

[0170] Drug loading (w / v) Example 3 Effective drug release (%) Comparative experiment 3 effective drug release (%) Treatment effect (inflammation reduction rate, %) 2.5% 80% 50% 80% 5% 75% 90% 50%

[0171] Expected results:

[0172] The optimized drug loading in Example 3 can ensure sustained release of the drug and maintain effective concentrations over a long period of time, making the therapeutic effect more stable.

[0173] The 5% drug loading in the control group resulted in too rapid drug release, a short duration of therapeutic effect, and a less stable drug efficacy than the present invention.

[0174] Summarize

[0175] This experimental design validated the innovative features of the present invention through single-factor comparisons, particularly the significant effects of pH-responsive and temperature-responsive nanoliposomes on drug release, permeability, particle size control, and loading optimization. Comparison with traditional drug delivery systems clearly demonstrated the advantages of the present invention in improving drug targeting, bioavailability, and therapeutic efficacy.

[0176] While embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions, and variations may be made to these embodiments without departing from the principles and spirit of the invention, and that the scope of the invention is defined by the appended claims and their equivalents.

Claims

1. A Chinese medicinal composition containing Angelica sinensis vine for treating rheumatoid arthritis, characterized in that: The preparation is made from the following raw materials in parts by weight: 30-50 parts of angelica vine; 10-20 parts of Achyranthes bidentata; 10-20 parts of Chuanxiong; 10-20 parts of white peony root; 5-10 parts of wolfberry fruit; 5-10 parts of raw rehmannia root.

2. A method for preparing a Chinese medicinal composition containing Angelica Root for treating rheumatoid arthritis, according to claim 1, wherein the Chinese medicinal composition containing Angelica Root for treating rheumatoid arthritis is characterized in that: The method comprises the following steps: pulverizing angelica vine, Achyranthes bidentata, Chuanxiong rhizome, white peony root, wolfberry fruit and raw rehmannia root; extracting effective components of the above medicinal materials by a solvent extraction method, wherein the extraction temperature is 40-60°C, the extraction time is 30-60 minutes, the solvent is 50%-70% ethanol, and the material-liquid ratio is 1:5-1:6, to obtain a drug extract; mixing the extract with phospholipids and a pH-responsive polymer, and preparing pH-responsive nanoliposomes by a thin film hydration method, wherein the pH-responsive polymer is polyvinyl alcohol or polyacrylate; and filtering and drying the pH-responsive nanoliposomes to obtain the Chinese medicine composition containing angelica vine for treating rheumatoid arthritis.

3. A method for preparing a Chinese medicinal composition containing Angelica Root for treating rheumatoid arthritis, wherein the Chinese medicinal composition containing Angelica Root for treating rheumatoid arthritis according to claim 1 is characterized in that: The method comprises the following steps: pulverizing angelica vine, Achyranthes bidentata, Chuanxiong rhizome, white peony root, wolfberry fruit and raw rehmannia root; extracting effective components of the above medicinal materials by solvent extraction; the extraction temperature is 40-60°C, the extraction time is 30-60 minutes, the solvent is 50%-70% ethanol, and the material-liquid ratio is 1:5-1:6, to obtain a drug extract, mixing the extract with phospholipids and a temperature-responsive polymer, and preparing temperature-responsive nanoliposomes by a layer-by-layer self-assembly method, wherein the temperature-responsive polymer is PNIPAM; and the temperature-responsive nanoliposomes are filtered and dried to obtain the Chinese medicine composition containing angelica vine for treating rheumatoid arthritis.

4. The method for preparing a Chinese medicinal composition containing Angelica Root for treating rheumatoid arthritis according to claim 2 or 3, characterized in that: The drug loading of the nanoliposomes is 1-5% (w / v).

5. The method for preparing a Chinese medicinal composition containing Angelica Root for treating rheumatoid arthritis according to claim 2 or 3, characterized in that: The pulverized particle size of the medicinal material is 30-50 meshes.

6. The method for preparing a Chinese medicinal composition containing Angelica Root for treating rheumatoid arthritis according to claim 2 or 3, characterized in that: The particle size of the nanoliposome is controlled at 100-200 nm.

7. The method for preparing a Chinese medicinal composition containing Angelica Root for treating rheumatoid arthritis according to claim 2 or 3, characterized in that: The extraction time of the extract is 30-60 minutes, and the extraction temperature is 40-60°C.

8. A Chinese medicine preparation for treating rheumatoid arthritis, characterized in that: The Chinese medicinal composition containing angelica vine for treating rheumatoid arthritis as claimed in claim 2 or 3 is prepared into pills or tablets.

9. Use of the traditional Chinese medicine preparation for treating rheumatoid arthritis according to claim 8 in preparing medicine for treating rheumatoid arthritis.

Images